What Is Candida Guilliermondii and What Does It Cause?

Candida guilliermondii is a yeast found naturally in soil, seawater, and on the skin of birds and other warm-blooded animals that occasionally causes bloodstream infections and other invasive diseases in people with weakened immune systems.¹ It accounts for a small fraction of all Candida infections worldwide, but its tendency to resist common antifungal drugs and its frequent misidentification in the lab make it more clinically significant than its rarity might suggest. The organism also has a surprisingly useful side: researchers have spent decades harnessing it for industrial production of xylitol and vitamin B2.

A Yeast With an Identity Crisis

For most of its history, this organism was simply called Candida guilliermondii. In the last couple of decades, genetic analysis revealed that it actually belongs to a species complex now formally named the Meyerozyma guilliermondii species complex, which includes at least three closely related species: Meyerozyma guilliermondii, Meyerozyma carpophila, and Meyerozyma caribbica.² Most clinical labs and older medical literature still use the name Candida guilliermondii, so you will see both names in practice. It belongs to the CTG clade of ascomycetous yeasts, a group that includes several medically important Candida species and shares a quirky genetic feature: these fungi have rewired one of their genetic code instructions so that a codon normally coding for one amino acid instead mostly codes for a different one.³ This does not directly matter for patients, but it helps explain why C. guilliermondii is grouped with certain other Candida species and studied alongside them.

The naming confusion goes beyond academic taxonomy. Standard laboratory identification systems routinely confuse C. guilliermondii with a related species, C. famata. In one study, 28 blood culture isolates initially identified by a widely used automated system were re-examined using more advanced methods. Every single one turned out to be C. guilliermondii, even though 25 of the 28 had been labeled C. famata by the original system.⁴ Even more advanced identification tools like MALDI-TOF mass spectrometry correctly identified only about three-quarters of isolates in that study. This means that some infections attributed to C. famata in clinical records are actually caused by C. guilliermondii, and the true burden of disease from this yeast is probably underestimated.

Where It Lives Naturally

C. guilliermondii is not a creature of hospitals alone. It has been isolated from a wide range of natural environments, including soil, sand, seawater, and swimming pools, as well as from the skin, feathers, and gastrointestinal tracts of birds and other warm-blooded animals.¹ It can also colonize human skin and nails without causing any symptoms. During an investigation of an apparent cluster of C. guilliermondii bloodstream infections at a Brazilian university hospital, researchers found the yeast on environmental surfaces throughout the facility and on the skin and nails of nursing staff. The episode turned out to be a pseudo-outbreak: none of the patients actually had clinical signs of fungal infection. Instead, the blood samples had been contaminated during collection, and the yeast had come from the environment and healthcare workers’ hands.⁵ That episode illustrates a key point: this yeast is commonly present in healthcare settings and on human skin without necessarily causing disease. It becomes dangerous when it gains entry to the bloodstream of someone whose immune defenses are down.

What Infections It Causes

The primary clinical concern with C. guilliermondii is candidemia, a bloodstream infection caused by Candida species. Globally, C. guilliermondii accounts for a small share of candidemia cases. In a large international surveillance study covering more than 75,000 Candida isolates collected between 2001 and 2003, C. guilliermondii represented about 1.4% of all isolates. The proportion was considerably higher in Latin America, where it reached 3.7%.⁶ Those numbers place it well behind C. albicans, C. glabrata, and C. parapsilosis in frequency, but its clinical significance comes from other factors.

Central venous catheters are the single most important gateway for this yeast to enter the bloodstream. In a study of patients with blood cancers, C. guilliermondii accounted for roughly 12% of candidemia episodes, and catheters were the documented source in about two-thirds of those cases.⁷ The yeast can adhere to catheter surfaces and establish itself there. Research on catheter-related candidemia has shown that non-albicans Candida species including C. guilliermondii tend to have high adhesion ability to catheter materials, though their capacity to form the dense protective communities known as biofilms varies between species.⁸ Lab studies have found that C. guilliermondii starts out with relatively sparse attachment to catheter surfaces in the first 24 hours, but can form mature biofilm by 48 hours.⁹

Beyond bloodstream infections, C. guilliermondii can cause endocarditis (infection of the heart valves), eye infections, bone and joint infections, and skin or wound infections, though all of these are uncommon. The bloodstream remains the overwhelmingly dominant site of serious infection.

Who Is Most Vulnerable

C. guilliermondii is an opportunistic pathogen, meaning it almost exclusively causes serious disease in people whose defenses are already compromised. A systematic review of candidemia caused by the M. guilliermondii species complex in cancer patients identified 282 cases, with roughly equal numbers involving blood cancers and solid tumors. The overall mortality in that group was 33%, and the number of reported cases increased sharply over the last two decades. The most common risk factors were having a central venous catheter in place (about 76% of cases), prior use of broad-spectrum antibiotics (around 69%), and receiving parenteral nutrition (about 46%).¹⁰

A broader literature review found over 500 reported cases of C. guilliermondii candidemia. Most patients were adults with multiple risk factors. Cancer chemotherapy was the leading predisposing condition, followed by catheter use and admission to an intensive care unit. Mortality rates in these reports ranged widely, from about 3% to as high as 67%, with cancer patients consistently faring worst.¹¹ Neonates and infants in intensive care units represent another at-risk group, particularly premature babies who often have central lines and immature immune systems.

For healthy people with intact immune systems, C. guilliermondii poses essentially no threat. It lives on skin and in the environment without causing harm. The transition from harmless colonizer to dangerous pathogen requires a substantial breakdown in immune defenses, prolonged hospitalization, or a direct pathway into the blood such as a catheter or surgical wound.

Drug Resistance and Treatment

One of the reasons clinicians pay attention to C. guilliermondii despite its rarity is its awkward resistance profile. The yeast tends to show reduced susceptibility to fluconazole, the antifungal most commonly used to treat Candida infections. It also shows diminished susceptibility to echinocandins, a class of drugs that is typically used as first-line therapy for serious Candida bloodstream infections.¹² This creates something of a treatment dilemma, since the two drug classes most clinicians would reach for first are both potentially compromised.

In practice, though, the picture is more nuanced than the resistance numbers alone suggest. A 12-year retrospective review at a reference laboratory found that a significant proportion of C. guilliermondii isolates, between roughly 10% and 20%, were classified as non-wild type for various triazole drugs. However, all isolates in that study were susceptible to micafungin, one of the echinocandins. About two-thirds of the patients in that cohort were immunocompromised, and roughly three-quarters of infections were hospital-acquired. Ten of 21 patients died within 60 days of their fungal bloodstream infection, though C. guilliermondii was considered the direct or partial cause of death in only four cases.¹³ The study’s authors suggested echinocandins as reasonable empiric therapy while waiting for susceptibility results.

A separate study at a tertiary hospital in Taiwan found a 30-day mortality of about 17% among patients with C. guilliermondii fungemia. In that analysis, keeping the central venous catheter in place rather than removing it was the single strongest independent risk factor for death.¹⁴ This aligns with the general principle in managing catheter-related candidemia: removing the infected line is often as important as choosing the right drug.

The somewhat paradoxical good news is that despite its resistance tendencies, C. guilliermondii appears to be a less virulent organism than the more common Candida species. It tends to form weaker biofilms and cause less tissue invasion, and clinical outcomes are often favorable when the infection is recognized and treated. One research group explicitly noted that while their C. guilliermondii isolates showed high antifungal resistance, the low virulence and poor biofilm formation were associated with favorable outcomes.¹²

How It Damages Host Tissue

Like other pathogenic Candida species, C. guilliermondii produces enzymes that help it invade tissue. Among the most studied are secreted aspartyl proteinases, enzymes that break down host proteins and help the yeast evade immune responses. Researchers have been working to identify which of these enzymes matter most for virulence. In one recent study, deleting a single proteinase gene from the C. guilliermondii genome reduced the yeast’s biofilm mass by roughly 39% and decreased mortality in a zebrafish infection model by about 17%, while also eliminating certain physical deformities seen in infected embryos.¹⁵ These proteinases are being studied as potential drug targets.

The human immune system does recognize C. guilliermondii, though not always as efficiently as it detects other Candida species. Research comparing immune responses to several Candida species found that C. guilliermondii had altered levels of certain cell wall sugars, and that human immune cells engulfed and responded to it through pathways that depend on recognition of those wall components.¹⁶ These differences in immune recognition help explain why host immune status is so critical: in a person with functional immune cells, these recognition pathways are usually enough to keep the yeast in check. In someone with depleted or suppressed immune function, the yeast can gain the upper hand.

Xylitol Production and Industrial Uses

C. guilliermondii has been studied for its biotechnological potential for over four decades.¹⁷ Its most commercially developed application is the production of xylitol, a sugar alcohol widely used as a low-calorie sweetener in chewing gum, toothpaste, and diabetic food products. Xylitol is conventionally manufactured through chemical hydrogenation of xylose, but the biological route using C. guilliermondii offers a potential alternative that can start from cheap agricultural waste.

The yeast naturally converts xylose, a sugar abundant in plant material like sugarcane bagasse, into xylitol. Researchers have scaled up this bioconversion from small bench-top flasks all the way to pilot-scale reactors holding 125 liters, achieving at least 60% conversion efficiency at each scale.¹⁸ Fine-tuning the sugar mixture matters: glucose, which is often present alongside xylose in plant-derived feedstocks, slows down xylose consumption by about 30%. Interestingly, arabinose, another sugar in the mix, does not interfere with xylose uptake and actually improves xylitol yield.¹⁹

Another industrial application involves riboflavin, better known as vitamin B2. C. guilliermondii is a natural riboflavin producer, and researchers have spent years trying to boost its output. Under iron-limited conditions, the yeast ramps up riboflavin synthesis dramatically. Genetic studies have identified key regulatory genes that, when disrupted, cause the yeast to overproduce riboflavin by five to seven times the normal amount even when iron is plentiful.²⁰ Earlier work found that adding certain amino acids or cobalt to the growth medium could also stimulate vitamin production, while iron and manganese inhibited it.²¹

Protecting Crops After Harvest

Beyond the lab flask and the hospital, C. guilliermondii has been studied as a biological control agent in agriculture. The idea is straightforward: instead of treating harvested fruits with chemical fungicides to prevent spoilage, coat the fruit with a living yeast that outcompetes the mold. In tests against Rhizopus stolonifer, a common bread mold that causes post-harvest rot in tomatoes, C. guilliermondii biomass applied to wound sites on the fruit surface provided 87% protection, preventing the pathogen from colonizing the damaged tissue.²² The yeast appears to work by rapidly colonizing wound sites before the mold can get established, physically and biochemically blocking pathogen germination. This approach fits within a broader movement toward biological alternatives to synthetic pesticides in food production, though commercial-scale adoption remains limited.

The dual nature of C. guilliermondii, as both an occasional human pathogen and a useful industrial organism, is not unusual in the microbial world. Many yeasts and bacteria that cause opportunistic infections in vulnerable patients are harmless or even beneficial in other contexts. For C. guilliermondii, the tension between its clinical and biotechnological sides is especially stark. The same organism that can threaten a leukemia patient on chemotherapy can also produce a sweetener for sugar-free gum and protect tomatoes from rotting on the shelf. Which face it shows depends almost entirely on the host it encounters and the circumstances of that encounter.